Orexo (ORX) Q4 2024 earnings summary

Executive summary

• Achieved positive EBITDA for both Q4 (SEK 28.9m) and full year (SEK 48.9m), a significant improvement driven by reduced OPEX and stable Zubsolv® revenues.

• Resolved long-standing Zubsolv® patent litigation with Sun Pharmaceuticals, allowing generic entry in September 2030 and eliminating short-term exclusivity risk.

• Impairment of digital mental health assets (Deprexis®, Vorvida®, Praxis, Bobeda, Modea) due to regulatory and reimbursement challenges, impacting net earnings.

• Internal transfer and revaluation of Zubsolv® US IP and manufacturing rights to a subsidiary, significantly increasing parent company equity.

• Stabilized subsidized revenues after prior declines, with Q4 sales similar to the previous year and sequential growth from Q3.

Financial highlights

• Q4 net revenues were SEK 160.3m (Q4 2023: SEK 166.0m); full-year net revenues reached SEK 590.0m (2023: SEK 638.8m).

• Q4 EBITDA was SEK 28.9m (Q4 2023: SEK 12.4m); full-year EBITDA was SEK 48.9m (2023: SEK -32.5m).

• Adjusted EBIT for Q4 was SEK 1.2m (Q4 2023: SEK -8.6m); US Commercial margin at 22.3%.

• Cash and cash equivalents at year-end were SEK 123.3m, up SEK 8.4m from Q3.

• Non-recurring write-down of SEK 99.2m for digital mental health program assets, impacting net earnings.

Outlook and guidance

• 2025 buprenorphine/naloxone market expected to grow 2–5%, similar to 2024's 3%.

• Zubsolv® net sales guidance for 2025 is USD 50–55m, reflecting Medicare uncertainties.

• OPEX for 2025 expected between SEK 460–500m; positive group EBITDA targeted.